196 related articles for article (PubMed ID: 35529441)
1. Biologics for Non-Cancer Dermatological Diseases: Analysis on China's Clinical Trial Registration Trend From 2016 to 2020.
Zhu B; Liu Y; Li J; Ni Q; Yin Z; Zhu J; Chen K; Yang X
Front Pharmacol; 2022; 13():817065. PubMed ID: 35529441
[No Abstract] [Full Text] [Related]
2. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011-2020).
Chen C; Lou N; Zheng X; Wang S; Chen H; Han X
Front Med (Lausanne); 2021; 8():777698. PubMed ID: 34977078
[No Abstract] [Full Text] [Related]
5. Characteristics and trends of clinical studies primarily sponsored by China in WHO primary registries between 2009 and 2018: a cross-sectional survey.
Xu Y; Dong M; Liu X
BMJ Open; 2020 Nov; 10(11):e037262. PubMed ID: 33444176
[TBL] [Abstract][Full Text] [Related]
6. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review.
Chen H; Zhou Y; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Mar; 8():100097. PubMed ID: 34327425
[TBL] [Abstract][Full Text] [Related]
7. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Zhong Q; Tao Y; Chen H; Zhou Y; Huang L; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Jun; 11():100151. PubMed ID: 34327360
[TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
9. Biologics for chronic inflammatory skin diseases: an update for the clinician.
Yao Y; Ravn Jørgensen AH; Thomsen SF
J Dermatolog Treat; 2020 Mar; 31(2):108-130. PubMed ID: 30827126
[TBL] [Abstract][Full Text] [Related]
10. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
Kaufman BP; Alexis AF
Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
[TBL] [Abstract][Full Text] [Related]
11. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Dobrić I
Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
Chingcuanco F; Segal JB; Kim SC; Alexander GC
Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
[TBL] [Abstract][Full Text] [Related]
13. Biological Therapies for Atopic Dermatitis: A Systematic Review.
Zhou S; Qi F; Gong Y; Zhang J; Zhu B
Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876
[TBL] [Abstract][Full Text] [Related]
14. Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
Bo C; Wang T; Hou C; Han J; Chen L; Zhang H; Wang L; Li H
CNS Neurosci Ther; 2022 Aug; 28(8):1229-1239. PubMed ID: 35642775
[TBL] [Abstract][Full Text] [Related]
15. Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023.
Jia W; Yu H; Song L; Wang J; Niu S; Zang G; Liang M; Liu J; Na R
Front Med (Lausanne); 2023; 10():1239351. PubMed ID: 38034540
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and completeness of clinical trial registrations in psoriasis and atopic dermatitis.
Quain RD; Katz KA
Br J Dermatol; 2007 Jan; 156(1):106-10. PubMed ID: 17199575
[TBL] [Abstract][Full Text] [Related]
18. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
19. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
20. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.
Hsu SH; Tsai TF
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):211-232. PubMed ID: 32167790
[No Abstract] [Full Text] [Related]
[Next] [New Search]
